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Abstract Adapter/scaffold proteins, through their multidomain
structure, perform a fundamental role in facilitating signal
transduction within cells. Paxillin is a focal adhesion adapter
protein implicated in growth factor- as well as integrin-mediated
signaling pathways. The amino-terminus of paxillin contains five
leucine-rich sequences termed LD motifs. These paxillin LD
motifs are highly conserved between species as well as within the
paxillin superfamily. They mediate interactions with several
structural and regulatory proteins important for coordinating
changes in the actin cytoskeleton associated with cell motility
and cell adhesion as well as in the regulation of gene
expression. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cell homeostasis is regulated through the integration of
extracellular signals impacting both growth factor- and adhe-
sion- or integrin-mediated receptor pathways. Engagement of
these receptors with their cognate ligands initiates multiple
convergent intracellular signaling cascades that give rise to a
variety of cellular responses including changes in gene expres-
sion, cell proliferation, modulation of cell shape and changes
in cell motility [1^3]. E⁄cient signal transduction, speci¢ca-
tion and ampli¢cation is e¡ected through the utilization of
selective sca¡old or adapter proteins which facilitate the as-
sembly of multi-protein signaling complexes. Although the
concept of sca¡old proteins was ¢rst invoked in the context
of growth factor signaling through the mitogen-activated pro-
tein kinase cascade [4], examples of similar multi-domain pro-
teins have emerged in the context of integrin-mediated signal-
ing events. One protein that has been suggested to function in
such an adapter/sca¡old capacity is the focal adhesion protein
paxillin (Fig. 1) [5]. This review will focus on a discussion of a
novel protein-binding domain, the LD motif, identi¢ed in the
N-terminus of paxillin, and detail its role in facilitating pax-
illin’s adapter function in the context of cell^extracellular ma-
trix-mediated signaling events.
2. The paxillin superfamily and LD motif structure
Paxillin is a 559 amino acid protein with an apparent mo-
lecular weight of 68 kDa. It is comprised of an N-terminal 313
amino acid domain that at ¢rst glance exhibits no obvious
sub-domain structure but contains several tyrosine and serine
phosphorylation sites important in integrin-mediated signaling
associated with cell adhesion, motility and growth factor sig-
naling [5]. The C-terminus is made up of four double zinc
¢nger LIM domains, which serve as binding sites for the ty-
rosine phosphatase PTP-PEST, tubulin and several uncharac-
terized serine/threonine kinases, and also contains the focal
adhesion targeting motif (Fig. 2) [5^8]. Paxillin was originally
identi¢ed in a screen for proteins tyrosine-phosphorylated by
the pp60v-src oncogene in Rous sarcoma virus-transformed
¢broblasts [9,10]. Subsequently it was characterized as a focal
adhesion protein with the capacity to bind directly to the
structural actin-binding protein, vinculin [10,11], as well as
the non-receptor tyrosine kinase FAK [12,13]. FAK repre-
sents an important transducer of integrin and growth factor
signaling being associated with regulation of cell proliferation,
cell motility and apoptosis [14]. The paxillin N-terminus con-
tains the binding sites for both vinculin and FAK [12,15].
Deletion mutagenesis studies delineated the speci¢c amino
acid sequences within paxillin that mediate these interactions
[15]. Interestingly, both vinculin and FAK were found to bind
to overlapping sequences, each of which contains a short leu-
cine-rich sequence with the general consensus LDXLLXXL.
In view of the conserved leucine and aspartic acid residues
(found in all the LD motifs except LD 3 where the LD is
substituted by a VE) they have been named LD motifs
[15,16]. This sequence is repeated ¢ve times within the paxillin
amino-terminus (Fig. 2). Furthermore, the LD motifs are
highly conserved throughout the paxillin superfamily mem-
bers, Hic-5, PaxB and Leupaxin, as well as being conserved
between species as diverse as Drosophila, Xenopus, and hu-
mans (Figs. 2 and 3) [16^20]. Indeed the highest level of con-
servation between all of these proteins is found within the LD
motifs and the LIM domains suggesting evolutionary conser-
vation of important structural domains. The diversity of the
paxillin family has recently been extended to include a trun-
cated protein comprising just the LIM domains of paxillin,
called DALP (death-associated LIM-only protein), perhaps
representing a natural antagonist to the function of the full
length protein (Fig. 2) [21].
Using structural modeling programs, the LD motifs of pax-
illin have been predicted to form an amphipathic, K-helical
structure with each of the leucine residues being positioned
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on one face of the helix thereby forming a hydrophobic pro-
tein-binding interface (Fig. 2B) [16,22]. Subsequent crystallo-
graphic or nuclear magnetic resonance studies will be required
to con¢rm this prediction. The paxillin LD motifs are evenly
distributed throughout the N-terminus. One intriguing possi-
bility raised by this arrangement is that the LD motifs may
function together in the recruitment of multiple signaling part-
ners into close proximity with each other to facilitate signal
propagation. Speci¢city may be imparted through the recruit-
ment of di¡erent combinations of proteins re£ecting the indi-
vidual signaling requirements arising as a result of di¡erent
external stimuli.
To determine whether the LD motifs could function as
speci¢c protein-binding motifs, each was expressed as a sepa-
rate GST-LD fusion protein and used in ‘pull-down’ assays.
From these experiments several observations are noteworthy.
First they con¢rmed that the LD motifs were indeed respon-
sible for the vinculin and FAK interactions with paxillin. Sec-
ond, they demonstrated the speci¢city of the interactions and
third that this speci¢city varied depending on the particular
binding partner involved. For instance, vinculin can bind to
LDs 1, 2 and 4 while FAK binding is restricted to LDs 2 and
4 [15,23]. This combination of redundancy and speci¢city has
been reinforced by the subsequent identi¢cation and charac-
terization of additional LD motif-binding partners including
paxillin kinase linker (PKL) which binds only to LD 4 [23],
Fig. 1. Paxillin subcellular localization in CHO K1 cells. Paxillin (green) localizes to focal adhesions at the ends of actin stress ¢bers (red).
Nuclei are labeled in blue.
Fig. 2. A: Paxillin superfamily members. Colors of LD motifs represent corresponding LD motifs conserved between family members. B: Paxil-
lin LD consensus (LDXLLXXL) modeled as an K-helix. Using Insight II 970 (MS1) molecular modeling software, the paxillin LD consensus
was modeled as an amphipathic helix. The conserved non-polar leucine residues are depicted in green and are arranged on one face of the
K-helix, presenting a hydrophobic-binding surface.
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integrin-linked kinase (ILK) which binds to LD 1 and the
actin-binding protein actopaxin which binds both LD 1 and
4 [24,25]. Importantly, the speci¢city of these interactions is
maintained when the LD motifs are presented in the context
of the intact paxillin protein. The FAK-related tyrosine kinase
PYK2 also binds paxillin. Although the binding parameters
are likely to be the same, which LD motifs are utilized for this
interaction remains to be determined. No binding partners
have thus far been identi¢ed for the paxillin LD 3 and LD
5 motifs.
Consistent with the high degree of conservation of sequence
between the LD motifs of di¡erent paxillin family members,
these proteins, as far as has been tested, interact with the same
complement of proteins. For instance Hic-5 binds vinculin,
FAK, PKL, and actopaxin [18,23,24,26] while the hemato-
poietic cell-speci¢c form of paxillin, leupaxin, binds PYK2
[17].
3. The paxillin-binding subdomain (PBS)
The binding module through which proteins interact with
paxillin LD motifs was ¢rst identi¢ed as a result of delineation
of the paxillin-binding sites on vinculin and FAK and was
named the paxillin-binding subdomain (PBS) [11,27]. Related
functional sequences have now been identi¢ed in the other
LD-binding proteins actopaxin, ILK, and PKL [24,25]. De-
tails of the structural and molecular interaction between the
PBS and the LD motif are unknown to date. It is evident,
however, from an alignment of these sequences that the PBS
domains are poorly conserved at the amino acid level when
compared with the LD motifs. Interestingly though, second-
ary structure predictions, using the Hierarchical Neural Net-
work, suggest that each of these PBS sequences forms an
K-helical structure £anked by regions of random coil. The
heterogeneity between the individual PBS domains may
form the basis for their selective binding to particular LD
motifs, alternatively such speci¢city may be provided by the
£anking sequences of both the PBS and the LD motifs.
4. Paxillin LD motifs and cell signaling
How does paxillin, through interaction with its LD motif-
binding partners, contribute to cell function and signaling?
First, mutagenesis of individual paxillin LD motifs or corre-
sponding PBS domains indicates that the interaction with
paxillin is essential for normal subcellular localization to focal
adhesions of vinculin, actopaxin, ILK and PKL [15,24,25].
Results from Tachibana et al. [27] suggest that this is also
the case for FAK targeting although this remains controver-
sial [28].
Interestingly, several of the paxillin LD motif-binding part-
ners function in the context of actin cytoskeleton dynamics.
For instance, both vinculin and actopaxin bind to F-actin
[24,29]. In the case of actopaxin, over-expression of a PBS
mutant defective for paxillin binding results in impaired cell
adhesion and cell spreading on collagen suggesting that the
ability of paxillin to recruit actopaxin to the plasma mem-
brane may be a critical step in an actopaxin-dependent nucle-
ation and assembly of actin ¢laments at these sites of cell
adhesion [24]. PKL is a member of a larger family of ARF
GAP proteins including GIT-1/2 [30,31]. PKL links paxillin,
through its LD 4 motif [23], to a complex of proteins com-
prising the Rac exchange factor, PIX/COOL [32,33] linked to
the p21 activated serine/threonine kinase, PAK and the SH2-
SH3 adapter protein Nck. PAK is an important mediator of
cytoskeletal reorganization associated with cell motility and
neurite outgrowth [34,35]. The importance of the PKL-paxil-
lin interaction in facilitating PAK’s function is suggested by
the abnormal cell morphology and reduced directed motility
of cells over-expressing either a paxillin LD 4 motif deletion
mutant or a PKL mutant lacking its PBS domain [36]. Addi-
tionally, the ability of paxillin to recruit GIT proteins to focal
adhesions may facilitate the disassembly of these structures,
thereby further enhancing cell motility [37]. The association of
PKL with the paxillin LD 4 motif has also been shown to be
necessary for PAK activation by the T-cell receptor [38].
As mentioned earlier, FAK is a critical regulator of cyto-
skeletal organization and focal adhesion turnover [39]. The
binding of FAK to paxillin is critical for e⁄cient FAK/Src-
dependent tyrosine phosphorylation of paxillin [40] which in
turn is necessary for cell motility in certain cell types [41] and
facilitates normal cell adhesion to ¢bronectin [42].
The serine/threonine kinase ILK plays a prominent role in
integrin- and growth factor-mediated signaling events. It is
involved in cell survival, cell growth control/transformation,
¢bronectin matrix assembly and epithelial^mesenchymal tran-
sition [43^45]. The signi¢cance of the ILK^paxillin interaction
in controlling these events through the ability of paxillin to
target ILK to focal adhesions [25] represents an important
Fig. 3. Amino acid sequence alignment of the amino-terminus of
paxillin from di¡erent species. Multi-alignment of amino acids 1^
322 of human paxillin against avian, Xenopus, and Drosophila forms
of paxillin. LD motifs are color coded in accordance with Fig. 1A.
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area for future study. Recent evidence for a direct interaction
between ILK and actopaxin [46,47,55] provides an additional
level of complexity.
Other than paxillin, Hic-5 has been the most extensively
studied paxillin superfamily member [18,48]. Hic-5 and pax-
illin share many of the same binding partners, but di¡er in
their ability to serve as substrates for tyrosine kinases. These
features combined with their frequent co-expression raise the
intriguing possibility that Hic-5 may at times complement and
at other times antagonize paxillin function. For instance, the
LD 3 motif of Hic-5, which corresponds to the paxillin LD 4
motif, is required for Hic-5-mediated inhibition of cell spread-
ing, possibly by sequestering FAK from paxillin [49].
Paxillin and its LD motifs also represent an important tar-
get for transforming DNA viruses such as papillomavirus,
which is the cause of a variety of dysregulated growth con-
ditions ranging from benign warts to malignant cervical can-
cers. Over-expression in ¢broblasts of the BE6 oncoprotein
produced by bovine papillomavirus leads to cell transforma-
tion and associated disruption of the actin cytoskeleton. This
is likely the result of a direct interaction between BE6 and the
paxillin LD motifs which in turn disrupts paxillin binding to
vinculin and FAK [50^52]. The paxillin^BE6 interaction is
necessary for the transforming capabilities of the E6 oncopro-
tein and the pathogenicity of the papillomavirus [51]. Since
BE6 binds preferentially to the LD 1 motif of paxillin [50] the
paxillin interactions with actopaxin and ILK may also be
compromised, although this awaits formal testing. Paxillin’s
interaction with BE6 has been shown, through mutational
analysis, to be mediated via a minimal LXXLL sequence with-
in its LD motif termed the ‘charged leucine motif’ [53,54].
This modi¢ed BE6^paxillin LD motif association may impart
a unique selective advantage for the BE6 protein over the
various physiologic LD motif-binding proteins.
5. Conclusions
There is now substantial evidence that the LD motifs within
the paxillin superfamily represent a discrete protein-binding
module. Their importance in facilitating integrin signaling
through interactions with a growing list of binding partners
is clear. Less certain is the more general utility of the LD
motif beyond the paxillin superfamily. A database search
for LD motif-containing proteins yields a limited number of
potential candidates, as does a similar search for proteins
containing PBS motifs [16]. Although this list represents an
interesting cross-section of structural and signaling proteins,
the ability of any of these molecules to utilize their LD or PBS
motifs in productive interactions with other proteins remains
to be determined.
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